Six-month gonadotropin releasing hormone (GnRH) agonist depots provide efficacy, safety, convenience, and comfort

Two different 6-month GnRH agonist depot formulations approved for palliative treatment of advanced and metastatic prostate cancer in the United States – leuprolide acetate 45 mg and triptorelin pamoate 22.5 mg – provide patients with efficacy and safety comparable to those of existing 1-, 3-, and 4...

Descripción completa

Detalles Bibliográficos
Autores principales: Crawford, E David, Phillips, Jason M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2011
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3154964/
https://www.ncbi.nlm.nih.gov/pubmed/21847353
http://dx.doi.org/10.2147/CMR.S12700

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3154964/
https://www.ncbi.nlm.nih.gov/pubmed/21847353
http://dx.doi.org/10.2147/CMR.S12700

Ejemplares similares